At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EXAS Exact Sciences
Post-Mkt 12-11 19:40:46 EST
101.36
+0.11
+0.11%
盘后101.32
-0.04-0.04%
19:07 EST
High101.52Low101.19Vol3.41M
Open101.28D1 Closing101.25Amplitude0.33%
Mkt Cap19.23BTradable Cap19.00BTotal Shares189.77M
T/O345.45MT/O Rate1.82%Tradable Shares187.46M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study
Reuters  ·  06:30
Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study
Exact Sciences, the Nsabp Foundation, and the German Breast Group Present Results for the Oncodetect® Mrd Test in Early Triple-Negative Breast Cancer at Sabcs
THOMSON REUTERS  ·  06:30
Exact Sciences, the Nsabp Foundation, and the German Breast Group Present Results for the Oncodetect® Mrd Test in Early Triple-Negative Breast Cancer at Sabcs
Illumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions
Reuters  ·  12-11 22:15
Illumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
Benzinga_recent_news  ·  12-06
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk
Simply Wall St.  ·  12-05
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk
Has Exact Sciences Rally of Over 50% Left Room for Further Upside?
Simply Wall St.  ·  12-05
Has Exact Sciences Rally of Over 50% Left Room for Further Upside?
REUTERS NEXT -Mizuho’s Katz sees 'fertile' conditions driving robust M&A market into 2026
Reuters  ·  12-04
REUTERS NEXT -Mizuho’s Katz sees 'fertile' conditions driving robust M&A market into 2026
Stifel Downgrades Exact Sciences to Hold From Buy, Adjusts Price Target to $105 From $80
MT Newswires Live  ·  12-01
Stifel Downgrades Exact Sciences to Hold From Buy, Adjusts Price Target to $105 From $80
Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts
TIPRANKS  ·  11-29
Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts
Exact Sciences downgraded to Hold from Buy at Stifel
TIPRANKS  ·  11-29
Exact Sciences downgraded to Hold from Buy at Stifel
TD Cowen Downgrades Exact Sciences to Hold From Buy, Adjusts PT to $105 From $90
MT Newswires Live  ·  11-25
TD Cowen Downgrades Exact Sciences to Hold From Buy, Adjusts PT to $105 From $90
U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital
Reuters  ·  11-25
U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital
Exact Sciences Corp : Canaccord Genuity Cuts to Hold From Buy; Raises Target Price to $105 From $85
THOMSON REUTERS  ·  11-25
Exact Sciences Corp : Canaccord Genuity Cuts to Hold From Buy; Raises Target Price to $105 From $85
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Reuters  ·  11-24
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Exact Sciences downgraded to Neutral from Overweight at Piper Sandler
TIPRANKS  ·  11-24
Exact Sciences downgraded to Neutral from Overweight at Piper Sandler
Exact Sciences Corp : Piper Sandler Cuts to Neutral From Overweight; Raises Target Price to $105 From $80
THOMSON REUTERS  ·  11-24
Exact Sciences Corp : Piper Sandler Cuts to Neutral From Overweight; Raises Target Price to $105 From $80
BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials
Reuters  ·  11-24
BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials
BUZZ-Jefferies cuts Exact Sciences to 'hold' after Abbott acquisition
Reuters  ·  11-24
BUZZ-Jefferies cuts Exact Sciences to 'hold' after Abbott acquisition
Exact Sciences Cut to Hold From Buy by Jefferies
Dow Jones  ·  11-24
Exact Sciences Cut to Hold From Buy by Jefferies
Benchmark Downgrades Exact Sciences to Hold From Buy
MT Newswires Live  ·  11-24
Benchmark Downgrades Exact Sciences to Hold From Buy

Introduction

Company Name.
Exact Sciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Issue price:
--